118 related articles for article (PubMed ID: 23138529)
61. Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer.
Schöffski P; Thate B; Beutel G; Bolte O; Otto D; Hofmann M; Ganser A; Jenner A; Cheverton P; Wanders J; Oguma T; Atsumi R; Satomi M
Ann Oncol; 2004 Apr; 15(4):671-9. PubMed ID: 15033678
[TBL] [Abstract][Full Text] [Related]
62. A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics.
Casulo C; Vose JM; Ho WY; Kahl B; Brunvand M; Goy A; Kasamon Y; Cheson B; Friedberg JW
Clin Immunol; 2014 Sep; 154(1):37-46. PubMed ID: 24928323
[TBL] [Abstract][Full Text] [Related]
63. Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer.
Shimizu T; Nishio K; Sakai K; Okamoto I; Okamoto K; Takeda M; Morishita M; Nakagawa K
Cancer Chemother Pharmacol; 2020 Aug; 86(2):211-219. PubMed ID: 32638093
[TBL] [Abstract][Full Text] [Related]
64. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors.
Eder JP; Ryan DP; Appleman L; Zhu AX; Puchalski T; He X; Sonnichsen DS; Cooper M; Wright J; Clark JW; Supko JG
Cancer Chemother Pharmacol; 2006 Jul; 58(1):107-16. PubMed ID: 16362299
[TBL] [Abstract][Full Text] [Related]
65. The pharmacokinetics of the antimigraine compound zolmitriptan in Japanese and Caucasian subjects.
Yates RA; Tateno M; Nairn K; Ikegami A; Dane A; Kemp J
Eur J Clin Pharmacol; 2002 Jul; 58(4):247-52. PubMed ID: 12136370
[TBL] [Abstract][Full Text] [Related]
66. Safety, tolerability and pharmacokinetics of shorter duration of infusion of obinutuzumab in Japanese patients with B-cell non-Hodgkin lymphoma: final results of the phase II GATS study.
Ohmachi K; Ando K; Kinoshita T; Kumagai K; Hatake K; Ishikawa T; Teshima T; Kato K; Izutsu K; Ueda E; Nakai K; Kuriki H; Tobinai K
Jpn J Clin Oncol; 2018 Aug; 48(8):736-742. PubMed ID: 30060000
[TBL] [Abstract][Full Text] [Related]
67. Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma.
Yamazaki N; Tsutsumida A; Takahashi A; Namikawa K; Yoshikawa S; Fujiwara Y; Kondo S; Mukaiyama A; Zhang F; Kiyohara Y
J Dermatol; 2018 Apr; 45(4):397-407. PubMed ID: 29399853
[TBL] [Abstract][Full Text] [Related]
68. Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer.
Ando M; Yonemori K; Katsumata N; Shimizu C; Hirata T; Yamamoto H; Hashimoto K; Yunokawa M; Tamura K; Fujiwara Y
Cancer Chemother Pharmacol; 2012 Feb; 69(2):457-65. PubMed ID: 21853310
[TBL] [Abstract][Full Text] [Related]
69. Comparison of the pharmacokinetics of fosfluconazole and fluconazole after single intravenous administration of fosfluconazole in healthy Japanese and Caucasian volunteers.
Sobue S; Tan K; Shaw L; Layton G; Hust R
Eur J Clin Pharmacol; 2004 Jun; 60(4):247-53. PubMed ID: 15103438
[TBL] [Abstract][Full Text] [Related]
70. Evaluation of the pharmacokinetics and safety of single and multiple ceftaroline fosamil infusions in healthy Chinese and Western subjects.
Yang L; Sunzel M; Xu P; Edeki T; Wilson D; Li J; Li H
Int J Clin Pharmacol Ther; 2015 Aug; 53(8):681-91. PubMed ID: 26152131
[TBL] [Abstract][Full Text] [Related]
71. Combination of YM155, a survivin suppressant, with bendamustine and rituximab: a new combination therapy to treat relapsed/refractory diffuse large B-cell lymphoma.
Kaneko N; Mitsuoka K; Amino N; Yamanaka K; Kita A; Mori M; Miyoshi S; Kuromitsu S
Clin Cancer Res; 2014 Apr; 20(7):1814-22. PubMed ID: 24486595
[TBL] [Abstract][Full Text] [Related]
72. Pharmacokinetics, Safety, and Preliminary Efficacy of Oral Trifluridine/Tipiracil in Chinese Patients with Solid Tumors: A Phase 1b, Open-Label Study.
Wang X; Zhou J; Li Y; Ge Y; Zhou Y; Bai C; Shen L
Clin Pharmacol; 2020; 12():21-33. PubMed ID: 32308505
[TBL] [Abstract][Full Text] [Related]
73. Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer.
Reigner B; Watanabe T; Schüller J; Lucraft H; Sasaki Y; Bridgewater J; Saeki T; McAleer J; Kuranami M; Poole C; Kimura M; Monkhouse J; Yorulmaz C; Weidekamm E; Grange S
Cancer Chemother Pharmacol; 2003 Sep; 52(3):193-201. PubMed ID: 12783206
[TBL] [Abstract][Full Text] [Related]
74. YM155 inhibits topoisomerase function.
Hong M; Ren MQ; Silva J; Paul A; Wilson WD; Schroeder C; Weinberger P; Janik J; Hao Z
Anticancer Drugs; 2017 Feb; 28(2):142-152. PubMed ID: 27754993
[TBL] [Abstract][Full Text] [Related]
75. Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors.
Murakami H; Doi T; Yamamoto N; Watanabe J; Boku N; Fuse N; Yoshino T; Ohtsu A; Otani S; Shibayama K; Takubo T; Loh E
Cancer Chemother Pharmacol; 2012 Sep; 70(3):407-14. PubMed ID: 22810805
[TBL] [Abstract][Full Text] [Related]
76. A phase I pharmacokinetic study of ursolic acid nanoliposomes in healthy volunteers and patients with advanced solid tumors.
Zhu Z; Qian Z; Yan Z; Zhao C; Wang H; Ying G
Int J Nanomedicine; 2013; 8():129-36. PubMed ID: 23319864
[TBL] [Abstract][Full Text] [Related]
77. Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors.
Takahashi T; Boku N; Murakami H; Naito T; Tsuya A; Nakamura Y; Ono A; Machida N; Yamazaki K; Watanabe J; Ruiz-Garcia A; Imai K; Ohki E; Yamamoto N
Invest New Drugs; 2012 Dec; 30(6):2352-63. PubMed ID: 22249430
[TBL] [Abstract][Full Text] [Related]
78. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors.
Ryan DP; Eder JP; Puchlaski T; Seiden MV; Lynch TJ; Fuchs CS; Amrein PC; Sonnichsen D; Supko JG; Clark JW
Clin Cancer Res; 2004 Apr; 10(7):2222-30. PubMed ID: 15073096
[TBL] [Abstract][Full Text] [Related]
79. Single- and multiple-dose pharmacokinetics, safety and tolerability of zibotentan (ZD4054) in Chinese men with advanced solid tumors.
Li J; Liu Y; Qian J; Wu L; Kemp J; Nii M; Tomkinson H; Zuo Y; Ranson M; Usami M
Cancer Chemother Pharmacol; 2012 Jul; 70(1):57-63. PubMed ID: 22618295
[TBL] [Abstract][Full Text] [Related]
80. A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma.
Cheson BD; Bartlett NL; Vose JM; Lopez-Hernandez A; Seiz AL; Keating AT; Shamsili S; Papadopoulos KP
Cancer; 2012 Jun; 118(12):3128-34. PubMed ID: 22006123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
